Yield10 Bioscience (Yield10 Bioscience) Total Assets : $3.91 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Total Assets?

Yield10 Bioscience's Total Assets for the quarter that ended in Dec. 2023 was $3.91 Mil.

During the past 12 months, Yield10 Bioscience's average Total Assets Growth Rate was -24.10% per year. During the past 3 years, the average Total Assets Growth Rate was -16.20% per year. During the past 5 years, the average Total Assets Growth Rate was -15.60% per year. During the past 10 years, the average Total Assets Growth Rate was -2.60% per year.

During the past 13 years, Yield10 Bioscience's highest 3-Year average Total Assets Growth Rate was 46.90%. The lowest was -23.00%. And the median was 0.10%.

Total Assets is connected with ROA %. Yield10 Bioscience's annualized ROA % for the quarter that ended in Dec. 2023 was -262.62%. Total Assets is also linked to Revenue through Asset Turnover. Yield10 Bioscience's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.

Yield10 Bioscience Total Assets Historical Data

The historical data trend for Yield10 Bioscience's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience Total Assets Chart

Yield10 Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

16.72

14.52

20.42

8.09

3.91

Yield10 Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															8.09	5.33	5.87	6.04	3.91

Yield10 Bioscience Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Yield10 Bioscience's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-2.483	+	6.39
	=	3.91

Yield10 Bioscience's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-2.483	+	6.39
	=	3.91

Yield10 Bioscience (NAS:YTEN) Total Assets Explanation

Total Assets is connected with ROA %.

Yield10 Bioscience's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-13.064	/	( (6.042	+	3.907)	/ 2 )
	=	-13.064	/	4.9745
	=	-262.62 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Yield10 Bioscience's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.06	/	( (6.042	+	3.907)	/ 2 )
=	0.06	/	4.9745
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Yield10 Bioscience Total Assets Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Yield10 Bioscience (Yield10 Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (NAS:YTEN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

M6X3:Germany

Address

19 Presidential Way, Woburn, MA, USA, 01801

Website

https://www.yield10bio.com

Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton	director	1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser	officer: VP Fin and CAO
Lynne H Brum	officer: VP Planning and Comms	21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell	officer: VP Research & CSO	C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey	director	C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples	director, officer: Pres & CEO	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin	director	21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully	10 percent owner	C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038